IMPACT OF VACCINATION WITH RIX4414 ON ROTAVIRUS GASTROENTERITIS (RVGE) IN CHILDREN AGED < 5 YEARS IN AUSTRALIA
Dr. MAJA GALIC
Disclosure : All authors are employees of GlaxoSmithKline Biologicals, which is the sponsor of the study.
8 slide(s) – English – 2011-06-07
BACKGROUND & AIMS:
Two licensed rotavirus vaccines are funded under the Australian National Immunisation Program (NIP) for all children born from 1 May 2007. We examined the impact of RIX4414 (Rotarix™, GlaxoSmithKline Biologicals) vaccination on rotavirus gastroenteritis (RVGE) hospitalizations in two states/territories: New South Wales (NSW), and the Australian Capital Territory (ACT).
A database analysis of state-based electronic hospital admissions was conducted to assess the trend of incidence rates of RVGE pre-introduction (1998-2006) with post-vaccination (2008-2009).
RIX4414 coverage increased after initial introduction, rising to 83.4% in NSW and 91% in ACT within the first year of implementation1. In 2009, incidence of RVGE in children <1 year decreased from a baseline of 35.85 to 2.69 per 10,000 child/year in NSW and 44.09 to 4.25 in ACT. The reduction of RVGE incidence was observed in all age groups (0-5 years). The overall reduction of RVGE in children <5 years in 2009 compared with baseline was 90.1% in NSW and 92.1% in ACT.
This study demonstrates significant reduction of RVGE hospitalizations after introduction of mass vaccination with RIX4414 in two Australian States/territories. Reduction of RVGE hospitalizations was observed in all children <5 years of age, even those were not eligible for vaccination according to their age, suggesting herd immunity.